These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 24743607)

  • 61. Targeted axillary dissection using carbon marking for patients with node-positive breast cancer following neoadjuvant therapy (TADCOM): study protocol for a prospective, multicenter, randomized controlled trial.
    Chen W; Pang L; Jin X; Chen H; Huang J
    BMC Cancer; 2024 Oct; 24(1):1276. PubMed ID: 39402559
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
    Javid S; Segara D; Lotfi P; Raza S; Golshan M
    Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients.
    Acea-Nebril B; García-Novoa A; Bouzón Alejandro A; Díaz Carballada C; Conde Iglesias C
    Breast; 2023 Dec; 72():103592. PubMed ID: 37857128
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
    Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
    Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value?
    Schipper RJ; van Roozendaal LM; de Vries B; Pijnappel RM; Beets-Tan RG; Lobbes MB; Smidt ML
    Breast; 2013 Dec; 22(6):1108-13. PubMed ID: 24095611
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer.
    Radovanovic Z; Golubovic A; Plzak A; Stojiljkovic B; Radovanovic D
    Eur J Surg Oncol; 2004 Nov; 30(9):913-7. PubMed ID: 15498633
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
    Wang L; Li Y; Li J; Wang T; Xie Y; He Y; Fan Z; Ouyang T
    Clin Transl Oncol; 2021 Feb; 23(2):240-245. PubMed ID: 32519177
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
    Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
    Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The sentinel node in breast cancer--a multicenter validation study.
    Krag D; Weaver D; Ashikaga T; Moffat F; Klimberg VS; Shriver C; Feldman S; Kusminsky R; Gadd M; Kuhn J; Harlow S; Beitsch P
    N Engl J Med; 1998 Oct; 339(14):941-6. PubMed ID: 9753708
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Aguayo-Albasini JL
    Cir Esp (Engl Ed); 2020 Nov; 98(9):510-515. PubMed ID: 32386728
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
    Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
    Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.
    Goyal A; Newcombe RG; Chhabra A; Mansel RE;
    Breast Cancer Res Treat; 2006 Sep; 99(2):203-8. PubMed ID: 16541308
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study.
    Munck F; Jensen MB; Vejborg I; Gerlach MK; Maraldo MV; Kroman NT; Tvedskov THF
    Ann Surg Oncol; 2024 Aug; 31(8):5157-5167. PubMed ID: 38704502
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer: a step towards conserving axilla?
    Arimappamagan A; Kadambari D; Srinivasan K; Krishnan R; Elangovan S; Reddy KS
    Indian J Cancer; 2004; 41(1):13-7. PubMed ID: 15105574
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
    Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
    Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment.
    Natsiopoulos I; Intzes S; Liappis T; Zarampoukas K; Zarampoukas T; Zacharopoulou V; Papazisis K
    Clin Breast Cancer; 2019 Jun; 19(3):208-215. PubMed ID: 30922804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.